Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. Orsi G, et al. Among authors: piacentini f. Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. Oncotarget. 2017. PMID: 28415563 Free PMC article.
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: piacentini f. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Frassoldati A, Guarneri V, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF. Frassoldati A, et al. Among authors: piacentini f. Clin Breast Cancer. 2008 Feb;8(1):97-100. doi: 10.3816/CBC.2008.n.010. Clin Breast Cancer. 2008. PMID: 18501066 Free article. Clinical Trial.
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.
Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'Amico R, Conte P. Guarneri V, et al. Among authors: piacentini f. Int J Biol Markers. 2010 Apr-Jun;25(2):104-11. doi: 10.1177/172460081002500208. Int J Biol Markers. 2010. PMID: 20544688 Free article.
Timing for starting second-line therapy in recurrent ovarian cancer.
Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Guarneri V, et al. Among authors: piacentini f. Expert Rev Anticancer Ther. 2011 Jan;11(1):49-55. doi: 10.1586/era.10.204. Expert Rev Anticancer Ther. 2011. PMID: 21166510 Review.
133 results